AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR
Key players in the Age-Related Macular Degeneration (AMD) drugs market include Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland)
The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust CAGR of 10.7%. This growth is driven by rising AMD prevalence linked to lifestyle changes, increased R&D investment leading to more drug approvals, and improved reimbursement policies. The market is particularly expanding in developing countries and is witnessing a shift towards innovative therapies like gene therapy. However, challenges like high treatment costs and the off-label use of drugs such as Avastin hinder market potential. Notably, Eylea remains the leading product, while dry AMD therapies are expected to grow rapidly due to escalating cases among the aging population. North America is projected to be the fastest-growing region, with significant annual AMD case increases. Key players include Regeneron, Bayer, and Novartis, among others, with recent developments indicating a strong focus on new therapeutic solutions.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37446234
Browse in-depth TOC on " Age-related Macular Degeneration (AMD) Drugs Market"
378 - Tables
54 - Figures
336 - Pages
Based on molecules, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into Ranibizumab, Aflibercept, Faricimab, Pegcetacoplan, and other molecules including conbercept, brolucizumab, avacincaptad pegol, and bevacizumab-gamma among others. In 2023, aflibercept held the largest share of the Age-Related Macular Degeneration (AMD) drugs market by molecule. This large share of the molecule can be attributed to the high adoption of this molecule for the treatment of the wet or neovascular form of AMD. This adoption is due to the high affinity of the molecule for VEGF proteins preventing activation of native VEGF receptors and reducing angiogenesis and vascular permeability. Moreover, the efficacy of the molecule is supported by various research studies comparing the effectiveness of this molecule to other molecules used for AMD treatment. Additionally, the ongoing development of novel drug delivery methods and biosimilars for this molecule further supports the growth of the market of this molecule.
Based on the type of AMD, the global Age-Related Macular Degeneration (AMD) drugs market has been segmented into wet AMD and dry AMD. In 2023, the wet AMD disease segment accounted for the largest share of the AMD market by type of AMD. The large share of wet AMD can be attributed to the rising prevalence of this disease affecting more than 20 million individuals globally. Reports from leading pharmaceutical companies highlight that more than 200,000 cases of wet AMD are reported in the US every year. This increase in wet AMD cases is attributed to the rising geriatric population with the World Health Organization (WHO) estimating a 2x increase in the number of individuals over 60 years of age by 2050. This market is also supported by new entrants targeting patients earlier in the disease cascade, with new drugs such as new entrants targeting patients earlier in the disease cascade with new drugs such as OPT-302 and KSI-301 being developed for the treatment of this disease.
Based on end users, the global age-related macular degeneration (AMD) drugs market has been segmented into hospitals, specialty centers, and long-term care facilities. Hospitals accounted for the largest share of the AMD drugs market by end user in 2023. The large share of this segment is attributed to the rising prevalence of AMD cases and the ability of hospitals to provide advanced healthcare infrastructure and specialized treatment capabilities that aid in the treatment of patients with AMD. Furthermore, hospitals also support research that facilitates the development of better treatment for various diseases including AMD. Hospitals collaborate with pharmaceutical companies to ensure the optimal availability of AMD drugs for patients while providing comprehensive care, including diagnostics, treatment administration, and patient monitoring to enhance treatment outcome for the patients.
The key regional markets for age-related macular degeneration (AMD) drugs market are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. In 2023, North America accounted for the largest share of the market. This can be attributed to the increasing AMD cases in the region with reports from major pharmaceutical companies highlighting the occurrence of more than 200,000 new cases of AMD every year in the US. A rise in obesity, smoking, and poor diet in this region further contributes to the increase in the number of AMD cases. Additionally, an increase in the number of approvals for AMD drugs in the region further supports the market growth. Advanced healthcare infrastructure in these regions, including access to specialists and diagnostic tools, supports early detection and treatment.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=37446234
The prominent players in the global Age-Related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc. (US), Bayer AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Apellis Pharmaceuticals (US), Coherus BioSciences (US), Astellas Pharma Inc. (Japan), Biogen (US), STADA Arzneimittel AG (Germany), Formycon AG (Germany), Biocon. (India), Outlook Therapeutics, Inc. (US), Intas Pharmaceuticals Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Chengdu Kanghong Biotech Company (China) and Sandoz Group AG (Switzerland). The market also includes players, such as Stealth BioTherapeutics Inc. (US), Ocular Therapeutix, Inc. (US), Opthea Limited (Australia), Kodiak Sciences Inc. (US), Innovent (China), Bio-Thera Solution (China), Alvotech (Iceland), Alteogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), Amgen Inc. (US), Ocumension Therapeutics. (China), and Adverum Biotechnologies, Inc. (US), that have drug candidates in phase 3 clinical trials.
Regeneron Pharmaceuticals Inc. (US):
Regeneron Pharmaceuticals Inc. is a biotechnology company that focuses on the development, manufacturing, and distribution of therapeutic drugs such as Eylea and Eylea HD (high dose) in the US for the treatment of various retinal disorders including wet Age-Related Macular Degeneration (wAMD). Eylea is one of the most adopted therapeutic drugs for the treatment of wet AMD across the globe. The company has partnered with major pharmaceutical companies such as Bayer AG to manufacture and distribute the drugs outside the US. Regeneron has operations in over 12 countries across the Asia Pacific, Europe, and North America, and conducts clinical trials in more than 60 countries. In 2023, the company allocated USD 96.2 million to improve Eylea HD, a higher hose of its already successful AMD drug Eylea. This drug allows patients to obtain similar therapeutic results with less number of injections reducing the treatment burden on the patients. The company has also developed innovative technologies like TRAPS and VelociSuite, which are used for the development of bispecific antibodies, essential for the development of next-generation ophthalmic drugs.
F. Hoffmann-La Roche Ltd (Switzerland):
Roche is a major pharmaceutical company that offers three FDA-approved drugs for the treatment of wet AMD among other retinal diseases: Lucentis, Vabysmo, and Susvimo, the company also provides Avastin (Bevacizumab) which is widely used as an off-label drug for the treatment of wet AMD owing to its affordability. In 2023, the company invested approximately 22% (USD 14.7 billion) of its annual revenue in R&D for the development of new drugs and exploring advanced research methods, including computational biology. The company has received marketing approvals for its AMD drugs in many countries, with recent expansions into markets like India. Roche's Genentech Ophthalmology Co-pay Program helps cover drug and administration costs making treatments more affordable. The company has operations in over 95 countries and offers a wide range of therapeutic products for a variety of diseases and disorders.
Novartis AG (Switzerland):
Novartis AG is a biotechnology company that focuses on the development and distribution of innovative medicines across key therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, ophthalmology, and oncology. In 2023, Novartis became a pure-play innovative medicines company by spinning off its Sandoz generic and biosimilar business unit. The company strongly focuses on ophthalmology, and markets FDA-approved drugs like Lucentis and Beovu (brolucizumab) for treating wet Age-Related Macular Degeneration (AMD) across the globe. Novartis is also conducting phase 3 clinical trials for Beovu to expand its use for diabetic retinopathy, highlighting the company's focus on innovation and expanding treatment options. The company operates in over 130 countries and uses contract structures such as pay-over-time and outcome-based agreements to make its products more affordable and accessible to patients.
For more information, Inquire Now!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
27 minutes ago
- Japan Forward
No Real Winner in Trump's Tariff War, Says Economist
President Donald Trump's sweeping tariffs have been sending ripples across the global trading system. Even a longtime American ally, Japan, was not spared. On July 23, Japan reached a deal with Washington under which the baseline tariff on Japanese goods was reduced to 15% from the initially proposed 25%. Sector-specific levies will remain in place, while Tokyo has committed to investing billions in the coming years. What impact will this have on Japan's export-driven economy, and what are Trump's ultimate motives? To explore these questions, JAPAN Forward sat down with Long Ke, an economist and senior fellow at the Tokyo Foundation. Excerpts of the interview follow. Since Tokyo was chosen as the Trump administration's first negotiating partner, there was a tendency toward overly optimistic expectations. Prime Minister Shigeru Ishiba himself probably believed that reaching an agreement would be straightforward, and the media suggested that if Japan secured a deal first, it would set a standard for other countries. Prime Minister Shigeru Ishiba meets with US President Donald Trump in Kananaskis, western Canada, on June 16. (©Cabinet Public Relations Office) Ishiba likely misread the situation, believing that Trump would lower tariffs as Japan was ready to invest heavily in American businesses. Looking back, Japan should have made concessions where necessary. For example, it initially refused to make any adjustments to expanding agricultural imports. Even in the automobile sector, it might have been better had the Japanese side offered to remove non-tariff barriers first. A tariff war is often a minus-sum game. The Trump administration believes the US has won because it's collecting substantial tariff revenue. That may be partially true, but some American companies are absorbing the tariffs themselves to avoid raising prices and shifting the burden onto consumers. In industries where Japanese companies are strong, Japan can pressure American trading firms to take on more burdens. But in sectors where Japan is weak, Japanese companies will need to manage the burdens themselves. With overall balance, it cannot be said that the US has achieved a complete victory. There are over 4,800 items traded between Japan and the US, and the impact of tariffs on each industry will need to be assessed individually. The "big deal" is set. Officials from relevant departments will now need to sort out the details. That said, a 15% baseline tariff would deal a good blow to Japan's export-driven companies, squeezing profit margins and undermining market competitiveness. Companies would likely struggle to raise general wages as a result. Various industries are being affected by inflation. A supermarket in Nerima-ku, Tokyo, on May 1, 2023. (©Sankei by Shunsuke Sakamaki) Regarding Japan's $550 billion USD investment in the US, Trump claims that 90% of the profits will accrue to the US. In investment, however, it is common sense that profits largely go to the investor. It's an enormous sum of money. And this isn't a lump-sum cash payment but rather a long-term investment in various projects. The two sides will settle on a project, build a factory, install and test the equipment, and only then will production begin. This isn't a process that can be completed in two or three years, and by the time the $550 billion investment is fully realized, Trump may no longer be in office. It depends on the time frame you're considering. Whether you focus on the short term or the long term makes a big difference. Many American companies still have inventory stockpiled after Trump's initial tariff threats, and some products remain untaxed. For now, major retailers like Walmart have generally not raised prices, making it difficult for small and mid-sized supermarkets to do so. However, once the Christmas and Thanksgiving season kicks in around November, inflation could start to accelerate. Another factor is that Washington and Beijing have yet to reach a full agreement, and only provisional measures are in place. For now, the risk of high inflation remains low. But what is likely to come first is a slowdown in the global economy. The US initially imposed a 145% tariff on China but gradually reduced it over time. Without this adjustment, inflation might have spiraled out of control. Most countries are expected to reach tariff agreements with the US by autumn. The key question is how these tariffs will ultimately be reflected in consumer prices. When discussing this issue, it's important to discern the true intentions of the US. When the US-China trade talks concluded in Stockholm in July, Treasury Secretary Scott Bessent stated that the US does not want to decouple from China but is seeking to rebalance unequal trade. Trump, on the other hand, seems primarily focused on maximizing tariff revenue and boosting the American economy. First, although US officials insist this is not a decoupling, in reality, the process is already underway. Factories assembling Apple iPhones, for example, are relocating to India, and its stores in China that sell iPhones directly have recently closed. Minister of State for Economic Revitalization Ryosei Akazawa with US Treasury Secretary Scott Bessent, US Secretary of Commerce Howard Lutnick, and US Trade Representative Jamieson Greer at the bilateral trade talks in May. (Pool photo via Kyodo) What about addressing the trade imbalance? While China's direct exports to the US are declining due to tariffs, shipments routed through third countries such as Vietnam, Malaysia, Indonesia, and others in Southeast Asia are rising. To that end, the US's overall trade deficit with the rest of the world may not shrink significantly. Meanwhile, Beijing is working to mitigate the impact by deepening trade with other nations, such as Brazil, which has also been hit with steep tariffs. If Trump's trade war aims to contain China, tariffs should not have been imposed on allies like Japan, South Korea, and the European Union. China imposed extremely strict lockdowns during the COVID-19 pandemic. Even after vaccines became available and the virus became less infectious, the measures were tightened further. As a result, roughly 4 million small and medium-sized businesses closed over the course of three years. Employment also deteriorated, making it difficult for many to find work. In June of this year, 11 million university students graduated, and about 60% of them were unable to secure a job. President Xi Jinping and Premier Li Qiang attend the closing ceremony of the National People's Congress in the Great Hall of the People in Beijing. (©Kyodo) Adding to that, in 2021, major Chinese real estate companies went bankrupt. This triggered the collapse of its real estate bubble, and the sector's downturn has been prolonged. While foreign exports normally help offset a weakening domestic market, Trump-era tariffs have made that path highly uncertain. As an authoritarian state, China presents its statistics in a polished manner. For example, economic growth for the first six months of this year was reported at 5.2%, but I believe the actual rate is closer to 2%–3%. Amid the harsh reality, rumors swirl that the Xi Jinping administration might collapse under the downturn. That, however, is an exaggeration. While the situation is certainly teetering on shaky ground, I don't see the Xi reign falling anytime soon. Author: Kenji Yoshida
The Market Online
5 hours ago
- The Market Online
BOMBSHELL! RENK, Bayer, Desert Gold! Who has the potential to multiply?
Bombshell at RENK! Order intake is exploding! Revenue and earnings are also already up significantly. After Rheinmetall and Hensoldt posted rather disappointing figures, the defense boom appears to be reaching the tank transmission specialist. The stock is reacting strongly. Meanwhile, the share price of gold explorer Desert Gold (TSXV:DAU) has not yet responded to the recent Preliminary Economic Assessment (PEA). This is surprising, as the returns are high – even with the conservative gold price assumptions. In an interview with analysts, the CEO once again explains the opportunities. GBC Research sees potential for multiplication here. At Bayer, investors have recently been focusing more on litigation risks in the US than on upside potential. However, the latest news from the pharmaceutical division is driving the Leverkusen-based company's shares up again. Is the weak phase finally over? This article is disseminated in partnership with Apaton Finance GmbH. It is intended to inform investors and should not be taken as a recommendation or financial advice. Desert Gold: An opportunity in the gold sector Desert Gold (TSXV:DAU) currently offers an opportunity in the gold sector. Last week, the long-awaited Preliminary Economic Assessment (PEA) for the SMSZ project in West Africa was published. Despite strong prospects, Desert Gold's share price has hardly reacted. Yesterday, Desert CEO Jared Scharf clarified in an interview with analysts from GBC Research that the study reflects only a fraction of the actual potential. According to this, only around 10% of the current gold resource of 1.1 million ounces was taken into account. Based on a gold price of USD 2,500 per ounce, the PEA calculates an internal rate of return (IRR) of 34% and an after-tax cash flow of USD 71 million. According to Scharf, the IRR is even above 50% at current prices. Thanks to low all-in sustaining costs of around USD 1,350 per ounce, the project has high leverage to the gold price. The reason for the 'small' PEA is that Desert is pursuing a modular processing strategy. Mobile open-pit mining equipment will enable the Company to start production quickly and remain flexible. The current permit allows for the processing of up to 36,000 tons per month – a capacity expansion is possible and could significantly accelerate cash flow. At the same time, the current gold resource of 1.1 million ounces at the SMSZ project could be significantly expanded. This is because only 5 of the more than 30 known gold zones have been included in the resource estimate to date. Scharf is also optimistic about Desert Gold's second project. Exploration is scheduled to begin after the end of the rainy season in Côte d'Ivoire. Link to interview. This should keep Desert Gold on track in terms of operations. Analysts at GBC Research see the fair value of the share at CAD 0.425. The security is currently trading at CAD 0.08 and is listed on Tradegate in Germany, among other places. RENK: One defense company that delivers At least one German defense company is already benefiting from the supercycle. RENK posted impressive figures for the first half of 2025 yesterday. The order intake in particular caused jubilation on the stock market, rising by 46.8% to EUR 921 million in the reporting period. Rheinmetall and Hensoldt had previously opened their books, and their order intake had caused disillusionment and led to hopes being pinned on the second half of the year. As a result, RENK shares rose by more than 5% yesterday. The Company, which is known for its transmissions for the Leopard 2 tank, also posted impressive operating results. Revenue rose by 21.5% to EUR 620 million. Adjusted EBIT climbed by 29.4% to EUR 89 million. With a book-to-bill ratio of 1.5x and a total order backlog of EUR 5.9 billion, visibility for the coming quarters has further improved. Given this strong performance, the forecast for the current year was (naturally) confirmed. RENK aims to increase revenue to over EUR 1.3 billion (2024: EUR 1.14 billion). EBIT is expected to be between EUR 210 million and EUR 235 million (2024: EUR 189 million). Bayer: Billion-dollar deal After uncertainty surrounding Bayer's court cases in the US caused its shares to fall last week, this week has seen a return to optimism thanks to positive developments in the pharmaceuticals division. Bayer shares rose by more than 4% yesterday alone. The reason: The Leverkusen-based company has signed a licensing deal with Kumquat Biosciences that could be worth billions. The US biotech company specializes in the KRAS signaling pathway. The KRAS signaling pathway is a central 'control center' in human cells that regulates how they respond to growth and division signals. It is one of the most frequently disrupted signaling pathways in cancer biology. Kumquat Biosciences is developing a small-molecule inhibitor designed to specifically block the KRAS G12D mutant. This mutation is particularly common in pancreatic, colon, and lung cancer and is currently difficult to treat medically. IND (Investigational New Drug) approval for the compound was granted by the US FDA in July 2025. Kumquat intends to conduct the Phase Ia study independently. Bayer will then take over the further development, approval, and marketing of the active ingredient. Bayer could pay Kumquat Biosciences up to USD 1.3 billion in total, but many milestones still need to be achieved. Desert Gold currently offers a great opportunity in the gold sector. The PEA has not yet triggered the expected price explosion, but a sharp upward move may be imminent. According to GBC Research, a multiplication is possible. After Rheinmetall and Hensoldt disappointed, particularly in terms of order intake, RENK's strong figures were important for the entire industry. Meanwhile, Bayer shares have already delivered a solid performance this year. Conflict of interest Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a 'Transaction'). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company. In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships. For this reason, there is a concrete conflict of interest. The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such. The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user. The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
The Market Online
5 hours ago
- The Market Online
Plug Power, Pure Hydrogen, RENK – The order books are filling up
The stock markets are celebrating as if there were no tomorrow. But caution is advised! The ambitious valuations of many companies are likely to result in a sharp correction in the near future. Stock picking is currently the order of the day, because we saw how quickly high prices can evaporate into thin air at the beginning of April when Donald Trump unveiled his tariff measures. But there are still some undiscovered gems out there. In the hydrogen sector in particular, a previously unknown company has made a name for itself with two future-oriented orders. This article is disseminated in partnership with Apaton Finance GmbH. It is intended to inform investors and should not be taken as a recommendation or financial advice. Plug Power – Red flags Plug Power was considered a beacon of hope for future-oriented fuel cell technology at the turn of the 2000s. The plans are still ambitious, as CEO Andy Marsh's company aims to benefit from the development of a comprehensive ecosystem for green hydrogen, ranging from production, storage, and delivery to energy generation. The ambitions have been euphoric ever since and have been regularly missed in recent years. Even with the recently published figures for the second quarter, the hydrogen specialist once again disappointed. Although revenue increased by 21.4% to USD 174 million, and the gross margin improved from minus 92% to minus 31%, the results still fell short of expectations. The improvement was due in part to rising demand and the implementation of the strategic restructuring program 'Project Quantum Leap,' which includes targeted cost reductions, improved service performance, and lower hydrogen prices. However, Plug Power once again fell short of expectations in terms of earnings per share, posting a loss of USD 0.20 per share, while analysts had expected a smaller loss of USD 0.15 per share. After an initial setback, Plug shares rose to the 200 EMA at USD 1.72, but were then sold off again despite a strong overall market environment. Pure Hydrogen – Two promising orders It is one thing after another for Australian hydrogen innovator Pure Hydrogen (GREY:PHCLF). The Company plans to offer hydrogen from domestic production in Australia and other countries. Together with its majority stake in HDrive International, Pure Hydrogen is also expanding its range of zero-emission products and implementing several solutions that enable commercial customers to switch to zero-emission vehicles. The cleantech company has received two significant orders for its hydrogen fuel cell vehicles, which is a clear sign of the growing interest in zero-emission heavy-duty transport in Australia. Of particular note is the purchase agreement with Scott Lovatt Transport, an established transport company based in New South Wales. The Company has ordered two TS70-400 'Taurus' prime mover trucks with a total value of over AUD 2 million. These vehicles are part of Australia's first fully licensed hydrogen truck fleet. Delivery is scheduled for mid-2026. The deal is still subject to conditions, in particular securing financing or government subsidies, but both parties are confident that access to these funds will be granted soon. The 'Taurus' truck represents a new generation in long-distance transport and is designed for real-world use in Australian heavy-duty transport. The second order comes from Heidelberg Materials Australia, one of the country's largest building materials companies. The Company has ordered another 8×4 concrete mixer truck with a hydrogen fuel cell after ordering the first vehicle of this type in March 2025. Delivery of the second vehicle is scheduled for the first quarter of 2026. The vehicles are based on the T30-200 platform and are equipped with a 200 kW fuel cell system, a CATL traction battery, and an 8×4 axle configuration specially designed for concrete transport. Both vehicles will be used in Rockingham, Western Australia, and are expected to significantly reduce operating emissions. With a market capitalization of AUD 41.08, the Company still has considerable upside potential, unlike companies such as Nel ASA and Plug Power, which remain overpriced. RENK – Defense hype reignited Is the correction that began at the beginning of the year at defense company RENK coming to an end with the announcement of its figures? From a technical perspective, the share price defended the significant EUR 60 mark and turned north. The MACD and relative strength index indicators are already back at 'Buy.' The next important hurdle would be the horizontal resistance in the EUR 69 range. RENK achieved significant growth in the first half of 2025 and further strengthened its position as a supplier in the defense sector. The Vehicle Mobility Solutions segment, which supplies transmission solutions for Leopard 2 tanks, among other things, recorded a significant increase in orders of 65.9% to EUR 681 million. Revenue in this segment rose by 32% to EUR 389 million, while EBIT grew by as much as 45.3% to EUR 67 million, with an EBIT margin of 17.1%. The US subsidiary RENK America also received a significant order worth USD 99 million from a long-standing customer in the defense sector. Driven by robust demand for defense equipment, the Augsburg-based company continued its growth course at the Group level. Order intake rose by 46.8% to EUR 921 million, and the order backlog reached a new record level of EUR 5.9 billion. Revenue grew by 21.5% year-on-year to EUR 620 million. Adjusted EBIT rose disproportionately by 29.4% to EUR 89 million, improving the Group margin from 13.5% to 14.4%. Fuel cell specialist Plug Power remains in the red. RENK benefits from the defense spending boom. Pure Hydrogen has reported two milestones. Conflict of interest Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a 'Transaction'). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company. In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships. For this reason, there is a concrete conflict of interest. The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such. The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user. The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
